Extended Data Fig. 7: Effects of UHRF1 or DNMT1 depletion in EBV+ primary effusion lymphoma, gastric carcinoma or nasopharyngeal carcinoma cells.
From: DNA methylation enzymes and PRC1 restrict B-cell Epstein–Barr virus oncoprotein expression
a, Immunoblot analysis of WCL from EBV+ and KSHV+ primary effusion cell line JSC-1 that expressed the indicated control, UHRF1 or DNMT1 sgRNAs or from MUTU III WCL as a control. b, 5 mC MeDIP analysis of chromatin from JSC-1 expressing control or UHRF1 sgRNA #2 followed by qPCR using primers specific for Cp or LMP1p. Mean ± SEM are shown for n = 3 biologically independent replicates. P values were calculated by unpaired two-sided student’s t-test with equal variance assumption. c, Immunoblot analysis of WCL from EBV+ NUGC3 gastric carcinoma cells that expressed the indicated sgRNAs. Quantification of EBNA2:GAPDH and LMP1:GAPDH ratios are indicated. d, Immunoblot analysis of WCL from EBV+ C666.1 nasopharyngeal carcinoma (NPC) cells that expressed the indicated control or UHRF1 sgRNAs or from MUTU III as a control. e, Immunoblot analysis of WCL from EBV+ C666.1 nasopharyngeal carcinoma (NPC) cells that expressed the indicated control or DNMT1 sgRNAs or from MUTU III as a control. f, 5mC MeDIP analysis of chromatin from C666.1 cells that expressed sgControl (gray boxes) or sgUHRF1 (black boxes) followed by qPCR using primers specific for Cp or LMP1p. Mean ± SEM are shown for n = 3 biologically independent replicates. P values were calculated by unpaired two-sided student’s t-test with equal variance assumption. Blots in a, c, d, and e are representative of n = 3 biologically independent replicates.
